Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1989 1
1991 1
1993 1
1997 2
1998 1
2000 1
2001 2
2002 1
2004 1
2008 1
2009 3
2012 1
2014 3
2015 2
2016 2
2017 1
2018 2
2019 1
2020 3
2021 3
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Noonan syndrome 14"
Page 1
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollmann TR, Lacerda MVG, Lee KJ, Lucas M, Lynn DJ, Manning L, Marshall HS, McDonald E, Munns CF, Nicholson S, O'Connell A, de Oliveira RD, Perlen S, Perrett KP, Prat-Aymerich C, Richmond PC, Rodriguez-Baño J, Dos Santos G, da Silva PV, Teo JW, Villanueva P, Warris A, Wood NJ, Davidson A, Curtis N; BRACE Trial Consortium Group. Pittet LF, et al. N Engl J Med. 2023 Apr 27;388(17):1582-1596. doi: 10.1056/NEJMoa2212616. N Engl J Med. 2023. PMID: 37099341 Free PMC article. Clinical Trial.
METHODS: In this international, double-blind, placebo-controlled trial, we randomly assigned health care workers to receive the BCG-Denmark vaccine or saline placebo and followed them for 12 months. ...The modified intention-to-treat population included 84.9% of the …
METHODS: In this international, double-blind, placebo-controlled trial, we randomly assigned health care workers to receive th …
GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome.
Dahlgren J, Albertsson-Wikland K. Dahlgren J, et al. Front Endocrinol (Lausanne). 2021 Nov 9;12:737893. doi: 10.3389/fendo.2021.737893. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34858328 Free PMC article.
BACKGROUND: Despite different genetic background, Noonan syndrome (NS) shares similar phenotype features to Turner syndrome (TS) such as short stature, webbed neck and congenital heart defects. ...GH was measured with poly- and monoclonal antibodies; 24hGH-pr …
BACKGROUND: Despite different genetic background, Noonan syndrome (NS) shares similar phenotype features to Turner syndrome …
The impact of growth hormone therapy on adult height in noonan syndrome: a systematic review.
Giacomozzi C, Deodati A, Shaikh MG, Ahmed SF, Cianfarani S. Giacomozzi C, et al. Horm Res Paediatr. 2015;83(3):167-76. doi: 10.1159/000371635. Epub 2015 Feb 21. Horm Res Paediatr. 2015. PMID: 25721697 Free article. Review.
BACKGROUND: Recombinant human growth hormone (rhGH) is being used to promote linear growth in short children with Noonan syndrome. However, its efficacy is still controversial. AIMS: To systematically determine the impact of rhGH therapy on adult height in children …
BACKGROUND: Recombinant human growth hormone (rhGH) is being used to promote linear growth in short children with Noonan syndrome …
The Effect of Growth Hormone Therapy on Cardiac Outcomes in Noonan Syndrome: Long Term Follow-up Results.
Kızılcan Çetin S, Ramoğlu MG, Şıklar Z, Özsu E, Aycan Z, Tutar HE, Berberoğlu M. Kızılcan Çetin S, et al. J Clin Res Pediatr Endocrinol. 2022 Dec 1;14(4):422-432. doi: 10.4274/jcrpe.galenos.2022.2022-12-13. Epub 2022 Jul 21. J Clin Res Pediatr Endocrinol. 2022. PMID: 35859537 Free PMC article.
OBJECTIVE: Cardiac involvement is common in Noonan syndrome (NS). Concerns have been raised regarding the effect of recombinant growth hormone (rGH) use on ventricular wall thickness and a possible increased risk of cardiac side effects. ...
OBJECTIVE: Cardiac involvement is common in Noonan syndrome (NS). Concerns have been raised regarding the effect of recombinan …
Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX, Tzeng CM. Huang WQ, et al. Curr Cancer Drug Targets. 2014;14(6):567-88. doi: 10.2174/1568009614666140717105001. Curr Cancer Drug Targets. 2014. PMID: 25039348 Review.
Dysfunction of SHP2 resulting from pathogenic mutations and aberrant expression leads to the dysregulation of multiple signaling pathways, thus contributing to different human disorders. Germline and somatic mutations in PTPN11 are involved in Noonan syndrome (NS), …
Dysfunction of SHP2 resulting from pathogenic mutations and aberrant expression leads to the dysregulation of multiple signaling pathways, t …
Diagnosis of Noonan syndrome and related disorders using target next generation sequencing.
Lepri FR, Scavelli R, Digilio MC, Gnazzo M, Grotta S, Dentici ML, Pisaneschi E, Sirleto P, Capolino R, Baban A, Russo S, Franchin T, Angioni A, Dallapiccola B. Lepri FR, et al. BMC Med Genet. 2014 Jan 23;15:14. doi: 10.1186/1471-2350-15-14. BMC Med Genet. 2014. PMID: 24451042 Free PMC article.
BACKGROUND: Noonan syndrome is an autosomal dominant developmental disorder with a high phenotypic variability, which shares clinical features with other rare conditions, including LEOPARD syndrome, cardiofaciocutaneous syndrome, Noonan-l …
BACKGROUND: Noonan syndrome is an autosomal dominant developmental disorder with a high phenotypic variability, which shares …
Developmental syndromes: growth hormone deficiency and treatment.
Mazzanti L, Tamburrino F, Bergamaschi R, Scarano E, Montanari F, Torella M, Ballarini E, Cicognani A. Mazzanti L, et al. Endocr Dev. 2009;14:114-34. doi: 10.1159/000207481. Epub 2009 Feb 27. Endocr Dev. 2009. PMID: 19293579 Review.
Developmental syndromes are characterized by numerous phenotypical signs and malformations. In most of them such as Turner, Noonan, Prader-Willi, Silver-Russel, Williams, Kabuki, Leri-Weill syndrome and skeletal dysplasias, short stature is a common feature. ...We r …
Developmental syndromes are characterized by numerous phenotypical signs and malformations. In most of them such as Turner, Noonan, P …
RASopathies and hemostatic abnormalities: key role of platelet dysfunction.
Di Candia F, Marchetti V, Cirillo F, Di Minno A, Rosano C, Pagano S, Siano MA, Falco M, Assunto A, Boccia G, Magliacane G, Pinna V, De Luca A, Tartaglia M, Di Minno G, Strisciuglio P, Melis D. Di Candia F, et al. Orphanet J Rare Dis. 2021 Dec 2;16(1):499. doi: 10.1186/s13023-021-02122-7. Orphanet J Rare Dis. 2021. PMID: 34857025 Free PMC article.
BACKGROUND: Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in patients with molecularly confirmed RASopathy. ...RESULTS: Regardless of the gene involved, pathological paediatric bleeding scores were recorde …
BACKGROUND: Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in pati …
Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up.
MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, Savage MO, McKenna WJ, Kelnar CJ. MacFarlane CE, et al. J Clin Endocrinol Metab. 2001 May;86(5):1953-6. doi: 10.1210/jcem.86.5.7468. J Clin Endocrinol Metab. 2001. PMID: 11344190
Growth data from the first 3 yr of a multicenter study examining the efficacy and safety of recombinant human GH [rhGH; 4 IU (1.3 mg)/m(2).day, sc] in children with Noonan's syndrome (NS) are reported for 23 subjects. Sixteen male and seven female patients (age, 9.3 …
Growth data from the first 3 yr of a multicenter study examining the efficacy and safety of recombinant human GH [rhGH; 4 IU (1.3 mg)/m(2).d …
Early Outcomes of Cardiac Surgery in Patients with Noonan Syndrome.
Hemmati P, Dearani JA, Daly RC, King KS, Ammash NM, Cetta F, Schaff HV. Hemmati P, et al. Semin Thorac Cardiovasc Surg. 2019 Autumn;31(3):507-513. doi: 10.1053/j.semtcvs.2018.12.004. Epub 2018 Dec 18. Semin Thorac Cardiovasc Surg. 2019. PMID: 30576779
There is a paucity of cardiac surgery outcomes data for patients with Noonan syndrome (NS). Our objective was to evaluate early results in these patients. ...The primary operations for the main diagnosis were pulmonary valve/conduit replacement/repair (n = 14 …
There is a paucity of cardiac surgery outcomes data for patients with Noonan syndrome (NS). Our objective was to evaluate earl …
36 results